Immunohistochemical (IHC) markers for breast cancer (e.g. estrogen and progesterone receptors, Ki67 proliferation marker, and HER2/neu testing) are currently used to guide therapeutic decision-making, classify breast cancer subtypes, and act as prognostic and predictive markers [1, 2]. This evidence concerns the gene PGR and breast carcinoma.